In certain Ras mutant cell lines the inhibition of ERK signalling increases RhoA 28 activity and inhibits cell motility, which was attributed to a decrease in Fra-1 29 levels. Here, we report a Fra-1 independent augmentation of RhoA signalling 30 during short-term inhibition of ERK signalling. Using mass spectrometry based 31 proteomics we identified the Rho exchange factor GEF-H1 as mediating this 32 effect. ERK binds to GEF-H1 and phosphorylates it on S959 causing inhibition 33 of GEF-H1 activity and a consequent decrease in RhoA activity. Knockdown 34 experiments and expression of a non-phosphorylatable S959A GEF-H1 mutant 35 showed that this site is crucial in regulating cell motility and invasiveness. Thus, 36
Introduction 40
Locomotion, and thus invasion and metastasis of tumour cells, is controlled by 41 cytoskeletal reorganisations, which are coordinated by the tightly regulated and 42 localised activation of the Rho family GTPases, namely RhoA, Rac and CDC42. Rac 43 and CDC42 are mainly activated at the leading edge, whereas RhoA activity is 44 localised at the rear and front of the moving cell (1-4). In cells randomly migrating on 45 two-dimensional surfaces RhoA activity precedes the formation of a protrusion, 46 whereas Rac1 and CDC42 activity peak shortly afterwards during the retraction phase 47
(1). Further, RhoA and Rac1 activities are inversely related due to mutual negative 48 feedback connections (5, 6) . 49
In three dimensional matrices cell motility has different characteristics than on two 50 dimensional surfaces and involves two distinct modes of invasion. Either cells are 51 elongated and move in a matrix metallo-protease (MMP) dependent mesenchymal 52 fashion, or the cells appear rounded and invade in a RhoA dependent, amoeboid way 53 (7) requiring high Rho-kinase (ROCK) activity. RhoA and ROCK control cellular 54 contractility, thus enabling the invading cell to squeeze through the extracellular 55 matrix without the need to degrade it by secreting MMPs. Cells can switch between 56 amoeboid and mesenchymal invasion (5, 8, 9) . 57
The rapid, spatially restricted and controlled activation/deactivation cycle of Rho 58 family GTPases is regulated by a balance of guanidine exchange factors (GEF) and 59
GTPase activating proteins (GAP). GEFs binding to RhoA release bound GDP, which 60 is replaced by abundant cellular GTP. GTP binding induces a conformational switch 61 that unmasks binding sites for downstream effectors. Termination of Rho signalling is 62 achieved through the binding of GAPs. These proteins associate with small GTPases and, by creating an active site, dramatically increase their intrinsic GTP hydrolysis 64 activity, thus reverting Rho family member to the inactive GDP bound state. GEF and 65 GAP activity as well as their sub-cellular localisation, is controlled by a multitude of 66 external signalling pathways, including Rho/Rac/CDC42 dependent signalling. This 67 high level of regulation, cross talk and complexity at the GEF/GAP level and the fact 68 that constitutively active GEFs have been identified as oncogenes, is driving extensive 69 research interest in these regulatory proteins (for a review see (10)). 70
Recently, GEF-H1 (ARHGEF2) was identified as an upstream regulator of leading-71 edge RhoA activity in migrating cells (11). Depletion of GEF-H1 by siRNA 72 decreased RhoA activity at the leading edge as well as random migration and focal 73 adhesion turnover. As with many GEFs, the regulation of GEF-H1 is complex 74 involving a multitude of phosphorylations on activating and inactivating sites. 75 Different kinases including PAK, Aurora A, Cdk1 and PAR1b (12-15) were shown to 76 inactivate GEF-H1 by phosphorylating inhibitory sites, whereas ERK (16, 17) was 77 reported to phosphorylate Thr678, an activating site. Interestingly, regulation of GEF-78 H1 activity downstream of ERK appears to be more complex, as inhibition of the 79 MAPK-pathway in unstimulated cells not only enhances RhoA activity but, 80 controversially, increases the phosphorylation of the reported ERK phosphorylation 81 site, Thr678 (18). Further, GEF-H1 is held in an inactive conformation when bound 82 to microtubules. Conversely, microtubule disassembly results in a robust activation of 83
RhoA via GEF-H1 (19) . 84
Here, we show that under growing conditions ERK phosphorylates GEF-H1 on an 85 inhibitory site. Inhibition of ERK signalling with chemical MEK-inhibitors induces 86 unphosphorylatable GEF-H1 mutant enhances RhoA activity and blocks cell 88 migration and invasiveness. In addition, preventing ERK inhibition of GEF-H1 89 induces cells to adopt a rounded morphology, and GEF-H1 downregulation interferes 90 with amoeboid invasion. 91 fractions were split, with one fraction subjected to Edman degradation and the other to 140 MALDI-mass spectrometry (MS). Edman degradation indicated that the major 141 phosphorylation site is located on position 6. MS analysis of the radioactive peptide 142 fraction was performed using a Bruker Ultraflex II TOF in positive ion mode using 143 dihyroxybenzoic acid as matrix. Resulting spectra were manually searched for tryptic 144 peptides with a modification of +80 and either S/T or Y on position 6. . 145
Materials and Methods
Alternatively, HEK293 or HCT116 cells transfected with GFP-GEF-H1 or vector, 146 incubated for 30 minutes with 10 μM U0126 or DMSO. Immunoprecipitated GEF-H1 147 was digested on the beads. After washing twice with 300 μL ice cold PBS, beads with 148 bound proteins were eluted in two steps. First, by using 60 µl of eluting buffer I (50 149 mM Tris-HCl pH 7.5, 2 M Urea and 50 µg/ml Trypsin (modified sequencing grade 150 trypsin, Promega) and incubated while shaking at 27°C for 30 minutes, and secondly 151 by adding two times 25 µl of elution buffer II (50 mM Tris-HCl pH 7.5, 2 M Urea and 152 1 mM DTT). Both supernatants were combined and incubated overnight at room 153
temperature. 154
Samples were alkylated (20 µl iodoacetamide, 5 mg/ml, 30 min in dark). Then, the 155 reaction was stopped with 1 μl 100% Trifluoracetic acid (TFA) and 100 µl of the 156 sample was immediately loaded into equilibrated handmade C18 StageTips 157 containing Octadecyl C18 disks (Supelco, Sigma UK). C18 StageTips, spin adaptors 158 and solvents were prepared as described previously (23). Samples were desalted by using two times 50 µl of 0.1% TFA and eluted with two times 25 µl of 50% AcN and 160 0.1% TFA solution. Final eluates were combined and concentrated until volume was 161 reduced to 5 µl using a CentriVap Concentrator (Labconco, USA). Samples were 162 diluted to obtain a final volume of 12 µl by adding 0.1% TFA and analysed by MS. 163
The tryptic peptides were analysed on a Thermo Scientific Q-Exactive mass 164 spectrometer connected to an Ultimate In order to explore if short-term inhibition of the ERK pathway regulates RhoA 200 activity we used HCT116 cells. HCT116 is a human colorectal adenocarcinoma cell 201 line containing a mutated KRAS G13D allele, which encodes a constitutively activated 202 protein leading to the chronic stimulation of downstream signalling. We showed 203 previously that HCT116 cells respond to prolonged MEK inhibition with a decrease in 204
Fra-1 and an increase in RhoA activity (24). As these observations were obtained after 205 overnight inhibition of MEK, we repeated the experiment at shorter time points in order to assess if acute inhibition of the ERK pathway suffices to augment RhoA-207 GTP. RhoA-GTP levels increased within half an hour of MEK inhibition as measured 208 by a Rhotekin-pulldown assay ( Fig. 1A ). Further RhoA activity peaked after one 209 hour, which coincided with a decrease in general ERK substrate phosphorylation 210 observed using an antibody that recognises the phosphorylated ERK consensus 211 sequence PXpSP ( Fig 1B) . Fra-1 levels did not decrease within this time period, but 212 only after prolonged MEK inhibition ( Fig 1C) . These results show that short term 213 inhibition of the ERK pathway is sufficient to increase RhoA activity without 214 downregulation of Fra-1 protein expression. Hence, we concluded that aside from 215 ERK-dependent RhoA regulation via Fra-1, another acute mechanism must exist. As 216 ERK substrate dephosphorylation and RhoA activation peak at the same time, we 217 hypothesised that an upstream activator of RhoA may be inhibited by ERK 218 phosphorylation. 219
ERK associates with GEF-H1 220
We previously mapped ERK1 interacting proteins by quantitative mass spectrometry 221 (MS) in PC12 cells (22) . Proteins that interacted with ERK1 in an EGF dependent 222 manner included the Rho exchange factor GEF-H1. To confirm the MS data we 223 immunoprecipitated endogenous ERK1 from serum starved and EGF stimulated PC12 224 cells and examined GEF-H1 association (data available upon request). GEF-H1 bound 225 to ERK1 in an EGF dependent manner. The association increased 5 minutes after 226 EGF addition and started decreasing at 15 minutes. Expressing exogenous Flag-227 tagged GEF-H1, we verified the dynamics of the interaction with ERK1/2 association 228 peaking at 5 minutes and subsiding to lower levels within 15 minutes (data available 229 upon request), correlating with EGF induced ERK activation dynamics.
Similarly, ERK and GEF-H1 interacted in HCT116 cells in an activation-dependent 231 manner ( Fig. 1D ). Both proteins could be co-immunoprecipitated in growing cells, 232 and the interaction was disrupted, if MEK and consequently ERK activity were 233 inhibited by U0126, thus confirming the results from PC12 cells. 234
235

ERK phosphorylates GEF-H1 on S959 236
ERK was recently reported to phosphorylate GEF-H1 on T678 and cause its 237 activation (16). By contrast, our results suggested that ERK signalling restricts GEF-238 H1 activation. Therefore, we determined whether ERK was phosphorylating 239 additional sites on GEF-H1. We introduced eGFP-tagged wild type (wt) GEF-H1 into 240 HEK293 cells and enriched the protein by immunoprecipitation. GEF-H1 can be 241 expressed to high levels in this cell line. Further, expression in a mammalian 242 expression system ensures that the protein is folded correctly. The 243 immunoprecipitated GEF-H1 was phosphorylated with activated recombinant ERK in 244 the presence of [ 32 P]--ATP (data available upon request). 32 P-labelled GEF-H1 was 245 digested with trypsin and the phosphopeptides were separated by HPLC. The 246 radioactive peptides eluted in two peaks (data available upon request). Edman 247 degradation of both peptide peaks indicated a phosphorylated amino acid at position 6 248 (data available upon request). Using MALDI-MS on the radioactive fractions, we 249 identified the peptide in the major first peak as LSPPHpSPR (data available upon 250 request), which corresponds to S959 in GEF-H1. 251
We did not identify T678, previously reported as an ERK site (16), in our in vitro 252 assay. This may have been due to low phosphorylation stoichiometry of T678, as the method used may fail to identify low abundant radiolabelled peptides. Attempts to 254 detect changes in the phosphorylation status of this site using a generic pTP antibody 255 were ambiguous. Therefore, we decided to quantify the phosphorylation sites by MS. 256
Similar to western blotting, MS quantification by itself is not able to determine 257 occupancy rates, but thanks to new analysis tools it is feasible to determine ratio 258 changes by comparing ion intensities across samples without the need to isotopically 259 label them. Thus, we used a label-free quantitative MS method to monitor intensity 260 changes of GEF-H1 phosphorylation in response to MEK inhibition, both in HEK293 261 (data available upon request) and HCT116 cells (Figs. 2A). We readily identified 262 multiple GEF-H1 phosphorylation sites in both cell lines. S959 phosphorylation 263 decreased in either cell line upon treatment with U0126. Conversely, T678 264 phosphorylation was cell type specific. In HEK293 cells the peptide phosphorylated 265 on T678 was readily identifiable, and represented the most intense ion of all the 266 phosphopeptides detected. In accordance to previous reports, U0126 was able to 267 reduce its phosphorylation. Additionally, we identified that phosphorylation of S695 268 was inhibited by U0126. Surprisingly, both sites were below the detection limit in 269 HCT116 cells, despite this cell line harbouring a hyperactivated MAPK pathway. 270
Thus, we concluded that in HCT116 cells the latter two sites appear not to be 271 phosphorylated or are phosphorylated to a level below the detection limit, implying 272 that the S959 is the major MEK dependent phosphorylation site in HCT116 cells. 273
Based on these data, T678 and S695 phosphorylation is cell type dependent. It has to 274 be noted that, despite complete inhibition of ERK phosphorylation for the duration of 275 one hour, a substantial amount of GEF-H1 is still phosphorylated on Ser959 in 276 HCT116 and HEK293 cells. The same holds true for Thr678 and Ser695 in HEK293 277 contributions from other kinases maintain GEF-H1 phosphorylation levels despite the 279 absence of ERK activity. 280
Due to the absence of T678 and S695 phosphorylation, we focussed on the 281 characterisation of S959, which is the major ERK-regulated GEF-H1 phosphorylation 282 site in HCT116 cells. S959 has been previously shown to be a direct substrate of 283 CDK1 and Aurora B as well as being required for PAR1b regulation of GEF-H1 284 activity (12, 14). First, we established that S959 is the major target phosphorylation 285 site for ERK in GEF-H1. GEF-H1 was constitutively phosphorylated in growing 286 conditions in HCT116 cells, ( Fig. 2A ). Phosphorylation was detected using an 287 antibody that selectively recognises a phosphorylated serine on a perfect ERK 288 consensus motif (PXpSP). This motif is unique to S959 within the GEF-H1 sequence, 289 and the phosphorylation signal could be reduced by about 50% by the U0126 and 290 PD0325901 MEK inhibitors (data available upon request). These results suggest that 291 GEF-H1 is phosphorylated by ERK on S959 in a MEK dependent manner. To 292 independently confirm the ERK-dependency of the S959 phosphorylation in another 293 cell line, we transfected MCF7 cells with wt and S-A Flag-GEF-H1 ( Fig. 2B ). In the 294 latter construct S959 was mutated to an alanine to prevent phosphorylation. The cells 295 were serum starved and stimulated with EGF in the presence or absence of a MEK 296 inhibitor. The phosphorylation of S959 increased within 5 minutes of EGF treatment. 297
The augmentation was blocked by U0126 confirming the MEK dependency that we 298 observed in HCT116 cells. No signal was detectable if S959 was mutated to alanine, 299 confirming the specificity of the PXpSP antibody, and that S959 is phosphorylated in 300 response to acute growth factor stimulation. Further, to demonstrate that the 301 reduction of S959 phosphorylation was not due to an off-target effect of U0126, we PD0325901 reduced EGF-induced S959 phosphorylation (Fig. 2C ). Having 304 established that ERK binds in an activation dependent manner and phosphorylates 305 GEF-H1 on S959 we wanted to ascertain if GEF-H1 contains any putative 306 ERK/MAPK binding motifs. ERKs can specifically bind to a DEF-motif and MAPKs 307 can bind to D-domains (26). We used Scansite 2.0 (27) to predict putative interaction 308 domains and phosphorylation sites of human GEF-H1. We detected both a DEF and 309 D-Domain in the C-terminus of the protein. In addition, only S959 and S955 were 310 predicted to be MAPK substrate sites (data available upon request). The DEF-domain 311 was not conserved across mammals, whereas both the predicted phosphorylation sites 312 and the D-domain are conserved ( Fig. 2D ). Thus, we found a conserved MAPK-313 binding and -phosphorylation site within vicinity of each other, suggesting that this is 314 the ERK-interaction domain which targets the C-terminal phosphorylation of GEF-315
H1. 316
Phosphorylation on S959 inhibits GEF-H1 activity 317 GEF-H1 has been shown to be regulated by phosphorylation on multiple sites (12-14, 318 16, 28). Interestingly, phosphorylation on both S885 and S959 were recently reported 319 to inhibit GEF-H1 activity (12, 14). Therefore, we examined the effects of wt GEF-320 H1 and the S959A (S-A) mutant on RhoA activity in growing HCT116 cells using 321
Rhotekin pull-downs assays (Figs. 2E & F). While expression of wt GEF H1 elevated 322
RhoA-GTP levels only marginally and insignificantly, the S-A mutation induced 323 significant increases, confirming previous reports that S959 is an inhibitory site (12, 324 14) . Surprisingly, the phosphomimetic S-D mutation also increased RhoA-GTP levels 325 to a similar extent as the S-A mutation. The similar effects of the non-326 phosphorylatable alanine and aspartate mutations indicate that size and negative charge of the carboxyl-group is insufficient to mimic the acidity and size of the 328 phosphoric acid residue. In these cases substitutions by alanine are functionally 329 equivalent to substitutions by phosphomimetic amino acids. Therefore, we conducted 330 subsequent experiments using the S-A mutant. In order to establish if whether another 331 phosphorylation site on GEF-H1 mediates the MEK-dependent regulation of its 332 activity, we transfected HCT116 cells with the wt and S-A mutant and treated the 333 cells with U0126. As expected, both the S-A mutation and U0126 treatment increased 334
RhoA activity in comparison to wt-transfected cells, whereas MEK-inhibition had no 335 effect on cells transfected with the S-A mutant (Fig. 2G ). This result suggests that 336 S959 is the main regulator of GEF-H1 activity downstream of the MAPK-pathway in 337 growing HCT116 cells. 338 GEF-H1 has been reported to bind to microtubules when inactive. Therefore, we 339 examined whether the inhibitory effect of S959 phosphorylation by ERK may be due 340 to induction of microtubule binding of GEF-H1. We transfected COS-1 cells with 341 eGFP-tagged wt and S-A mutant and treated the cells with 10 μM U0126 or DMSO. 342
In accordance to previous reports, we detected wt GEF-H1 localised at microtubules 343 and at the plasma membrane. Treatment with U0126 or the S-A mutation changed the 344 localisation only marginally to a more diffuse cytoplasmatic localisation. The change 345 in localisation was only slight (data available upon request). Therefore, we cannot 346 conclude that the inhibitory effect of S959 phosphorylation is due to induction of 347 microtubules binding. In order to test this hypothesis, we knocked down GEF-H1 by siRNAs or inhibited the 365 ERK pathway using a chemical MEK inhibitor, and monitored RhoA activity by 366
Rhotekin pull-down experiments (Fig. 3A) . Knocking down GEF-H1 approximately 367 halved the basal RhoA activity. Moreover, RhoA-GTP levels increased upon 368 administering the U0126 MEK inhibitor in a time dependent manner. Intriguingly, 369 this increase was completely blocked by GEF-H1 downregulation. Thus, at least half 370 of the RhoA activity in growing MDA-MB-231 cells is due to GEF-H1, while the 371 increase in RhoA-GTP induced by short-term MEK inhibition is completely 372 dependent on GEF-H1. In order to show that the observed increase of RhoA upon 373 MEK inhibition is not due to an off-target effect, we treated MDA-MB-231 cells with 374 an alternative MEK-inhibitor and were able to show that both U0126 and PD0325901
show that both inhibitors reduce GEF-H1 S959 phosphorylation and ERK binding in 377 MDA-MB-231 cells (Fig. 3C) . 378
To test the role GEF-H1 plays in invasion we over-expressed wt and S-A mutant 379 GEF-H1 in MDA-MB-231 cells by transient transfection. Over-expression of wt 380 GEF-H1 did not significantly affect three-dimensional invasion into Matrigel or RhoA 381 activity, whereas the S-A mutant inhibited invasiveness and increased Rho-GTP 382 levels ( Fig. 3D -E, tiled images of sections available upon request). Likewise, U0126 383 and PD0325901also severely reduced invasion (Fig. 3F) . 384
Interestingly, GEF-H1 S-A and MEK inhibition not only decreased the invasiveness 385
of MDA-MB-231 cells, but also changed the morphology of the remaining invasive 386 cells from an elongated, mesenchymal into a rounded phenotype (Fig. 3G) , which is 387 indicative of high RhoA activity. The cells expressing GEF-H1 S-A or treated with 388 MEK inhibitor appeared rounded, very similar to A375-M2 cells, which exhibit the 389 prototypical amoeboid mode of invasion (30), suggesting that GEF-H1 hyperactivity 390 switches invading cells to the amoeboid morphology. 391
As the transition from a mesenchymal to an amoeboid phenotype could be induced by 392 either a hyper-active GEF-H1 or MEK inhibition, we hypothesized that knocking 393 down GEF-H1 should rescue some effects of MEK inhibition; i.e. promote invasion 394 and/or inhibit the transition to the round phenotype. Inhibition of RhoA activation by 395 TAT-C3 or knockdown of GEF-H1 partially salvaged cell invasion inhibited by 396 U0126 or PD0325901 (Figs. 4A, B , tiled images of sections available upon request). 397
Additionally, the change in morphology was indeed RhoA dependent as we could 398 rescue the phenotype with TAT-C3 or GEF-H1 downregulation (Figs. 4C & D) . We inhibition is transmitted via GEF-H1 being dephosphorylated on S959, which leads to 401 an increase in GEF-H1 and consequently RhoA activity, inducing the cell shape 402 changes in a 3D matrix. 403
GEF-H1 is dispensable in mesenchymal but essential in amoeboid invasion 404
The reversal of the U0126 induced morphological transition by GEF-H1 depletion 405
suggested that GEF-H1 may promote amoeboid invasion. Thus, we investigated how 406 GEF-H1 knockdown by siRNA influenced mesenchymal and amoeboid invasion. 407
Notably, the reduction of GEF-H1 had opposite effects on mesenchymal and 408 amoeboid invasion. Reduced expression of GEF-H1 in the mesenchymally and 409 collective invading cell-line MDA-MB-231 increased their invasive potential by 410 ~60% (Fig. 5A , tiled images of sections available upon request). In contrast, the 411 invasion of A375M2 cells, which predominantly invade amoeboidly, was more than 412 halved ( Fig. 5B , tiled images of sections available upon request). This observation 413 indicates that GEF-H1 is dispensable (and maybe even inhibitory) for mesenchymal 414 invasion, but necessary for amoeboid invasion. Therefore, we speculated that if we 415 were able to induce a mesenchymal-amoeboid-transition (MAT) in MDA-MB-231 416 cells, their invasion should switch from a GEF-H1-independent to a GEF-H1-417 dependent mechanism. Mesenchymal invasion requires the degradation of 418 surrounding tissue or matrix by the matrix-metallo-proteases (MMPs), and evidence 419 suggests that MAT can be induced by inhibiting MMPs (31). Applying the broad-420 band MMP inhibitor GM6001, the cells became rounded and morphologically 421 underwent MAT (Figs. 5C). When we reduced GEF-H1 levels with siRNA and 422 monitored both MDA-MB-231 morphology and motility, GM6001 not only induced 423 request). GEF-H1 knockdown in combination with GM6001 did not further inhibit 425 invasion but induced an amoeboid-mesenchymal-transition (AMT), characterised by 426 the reappearance of elongated, mesenchymal cells in the invading fraction (Fig. 5C ). 427
In contrast to MAT induced by MEK inhibition, the knockdown and subsequent AMT 428 did not rescue the invasiveness of the cells, probably because the presence of MMP 429 inhibitors prevented the degradation of the Matrigel required for efficient 430 mesenchymal invasion. The rounding of the cells is apparently independent of the 431 ERK-pathway, as GM6001 treatment on its own only marginally reduced ERK 432 phosphorylation in MDA-MB-231 ( Fig. 5E ). 433
Taken together these data confirm our hypothesis that GEF-H1 can drive amoeboid 434 invasion and is pivotal for MAT induced by MMP inhibitors 435
Discussion
436
In migrating cells, leading edge RhoA activity regulates the protrusion dynamics. This 437 highly dynamic process requires a fast response to intrinsic and extrinsic stimuli as 438 well as coordinated cycling between active and inactive states. Previous studies have 439 revealed a mutual antagonism between Rac and Rho signalling, whose coordination is 440 important for the regulation of cell motility, invasiveness and mode of invasiveness 441 (for a recent review see (31)). High Rac activity promotes the mesenchymal mode of 442 invasion, while high Rho activity facilitates amoeboid movement. The chain of events 443 regulating Rac activation in migration was recently elucidated as a cascade of the 444 adaptor protein NEDD9 recruiting the Rac-specific GEF DOCK3, which activates 445 Rac1 (5). However, the GEF, which activates Rho, is unknown. Our data suggest that 446 this GEF is GEF-H1. Matrigel as elongated cells in a mesenchymal fashion. Inhibition of the ERK pathway 473 almost completely prevents the cells from invading towards an EGF or serum 474 gradient, and more interestingly, also causes the cells to change their morphology. 475
They become rounded and resemble cells which invade in an amoeboid fashion. This 476 change in shape is also enforced by expressing a GEF-H1 mutant that cannot be 477 phosphorylated on S959. This change in morphology, and to a lesser extent the 478 deficient motility, can be rescued by either suppressing RhoA signalling or by 479 reducing endogenous levels of GEF-H1. Taken together, these data reveal a 480 mechanism how ERK can regulate cell motility and invasiveness by crosstalking to 481 the RhoA pathway ( Fig. 6 ). They also suggest that the transition of a mesenchymal to 482 amoeboid morphology can be induced by GEF-H1, and that amoeboid invasion in 483 A375M2 cells is dependent on GEF-H1. 484 GEF-H1 is frequently expressed to high levels in cancers (www.proteinatlas.org), and 485
we were surprised to find that GEF-H1 expression was subduing the invasive 486 potential of MDA-MB-231 cells. A plausible explanation is that the ability of cancer 487 cells to switch between mesenchymal and amoeboid modes of movement may be 488 advantageous to invade surrounding tissue. GEF-H1 can be easily inactivated by high 489 ERK activity when mesenchymal invasion is preferred. On the other hand, high levels 490
of GEF-H1 activity will facilitate transition to an amoeboid type of invasion. This 491 plasticity would enable a cell to maintain high invasive motility regardless of its 492 environment. 
